Compare GSK plc (GSK) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Iron Mountain Inc — how do they compare? GSK plc trades at $46.41 (market cap $91.88B), while Iron Mountain Inc trades at $114.34 (market cap $34.46B). The key difference: GSK plc is far larger — about 2.7× Iron Mountain Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Iron Mountain Inc for 80 Days on average.
| GSK | IRM | |
|---|---|---|
Market Cap | $91.88B | $34.46B |
Volume | 7,730,529 | 1,379,608 |
Sector | Health | Real Estate |
52-Week High | $61.18 | $133.06 |
52-Week Low | $43.24 | $78.86 |
Typical Hold Time | 93 Days | 80 Days |
Enterprise Value | $111.88B | $53.87B |
Dividend Yield | 3.9% | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong institutional interest. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed. Recent news highlights expansion in data centers and digital partnerships, including a 300MW pipeline and AI collaborations.
The outlook is supported by analyst consensus with a $142.75 price target (66.7% buy ratings), but high debt levels and elevated P/E of 82.09 pose risks. Earnings growth from digital initiatives is the key catalyst, while leverage and margin pressure require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
